Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A subunit vaccine for multiple respiratory viruses.

Science advances·2026
Same author

Noninvasive whole-brain imaging of glymphatic dynamics.

Science advances·2026
Same author

Immunogenicity of <i>Theileria parva</i> p67C Antigen Delivered via Adjuvanted CoPoP Liposomes in Cattle and Mice.

Vaccines·2026
Same author

Mesoscopic Fluorescence Imaging of Light-Triggered Chemotherapeutic Release in Cancer Spheroid Models.

Pharmaceutics·2026
Same author

Enhancing antitumour nanovaccine efficacy via integrated cholesterol modulation in situ.

Nature nanotechnology·2026
Same author

Preparing Adjuvanted Nanoliposomes for Applications Toward Recombinant Influenza Vaccine Development.

Bio-protocol·2026

Related Experiment Video

Updated: Dec 12, 2025

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

13.0K

Engineered Nanoparticle Applications for Recombinant Influenza Vaccines.

Zachary R Sia1, Matthew S Miller2, Jonathan F Lovell1

  • 1Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York 14260, United States.

Molecular Pharmaceutics
|August 14, 2020
PubMed
Summary

Next-generation influenza vaccines may combine recombinant antigens with nanoparticle carriers to improve immunogenicity and provide broad protection against emerging viral strains.

Keywords:
antigensinfluenzananoparticlesparticlesvaccine

More Related Videos

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System
12:18

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System

Published on: November 6, 2013

24.6K
Generation of Recombinant Influenza Virus from Plasmid DNA
11:31

Generation of Recombinant Influenza Virus from Plasmid DNA

Published on: August 3, 2010

31.6K

Related Experiment Videos

Last Updated: Dec 12, 2025

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

13.0K
Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System
12:18

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System

Published on: November 6, 2013

24.6K
Generation of Recombinant Influenza Virus from Plasmid DNA
11:31

Generation of Recombinant Influenza Virus from Plasmid DNA

Published on: August 3, 2010

31.6K

Area of Science:

  • Vaccinology
  • Nanomedicine
  • Virology

Background:

  • Influenza viruses cause seasonal epidemics and pose pandemic threats.
  • Current vaccines struggle to protect against emerging strains, necessitating broad-protection vaccine development.
  • Recombinant biotechnology and nanomedicine offer potential for enhanced influenza vaccine immunogenicity.

Purpose of the Study:

  • To explore the potential of combining recombinant antigens with nanoparticle carriers for next-generation influenza vaccines.
  • To review nanoparticle-based vaccine strategies for improved immune response against conserved influenza antigens.

Main Methods:

  • Review of current research on nanoparticle candidates for vaccine development.
  • Analysis of various nanoparticle types: virus-like particles, nanoconstructs, lipid particles, and modified inorganic particles.
  • Evaluation of methods for antigen presentation on nanoparticles.

Main Results:

  • Nanoparticle-based vaccine approaches have shown promising results in animal models.
  • Demonstrated protection against antigenically distinct influenza strains.
  • Successful production of broadly reactive antibodies and activation of potent T cell responses.

Conclusions:

  • Combining recombinant antigens with nanoparticle carriers is a feasible strategy for next-generation influenza vaccines.
  • Nanoparticle delivery systems can enhance immunogenicity and target conserved viral epitopes.
  • This approach holds promise for broad protection against diverse influenza strains.